Quintiles buys Bioglan subsidiary assets

QTRN acquired most of the assets of Bioglan Pharma Inc., the U.S. subsidiary of Bioglan Pharma Plc (LSE:BGP), for $26.7 million in cash. Included in the deal were North American marketing rights to de...